Overview

Treatment of Hemorrhagic Fever With Ribavirin

Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Multisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command
Treatments:
Ribavirin